Inhibition of the TNF-α/IDO1 Axis Restores Brain Serotonin and Mitigates Aggression-like Phenotypes in BCG-inoculated Mice

preprint OA: closed
Full text JSON View at publisher

Abstract

Abstract Aggression is linked to systemic inflammation and serotonergic dysfunction. Tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine, disrupts serotonin synthesis by upregulating indoleamine 2,3-dioxygenase 1 (IDO1), which diverts tryptophan metabolism away from serotonin production. This study investigated whether inhibiting the TNF-α/IDO1 signaling pathway could reduce aggressive behavior. Aggression-like behaviors were induced in mice using Bacillus Calmette–Guérin (BCG), known to elevate systemic TNF-α and reduce brain serotonin. Behavioral assessments included the Social Aggression Test (SAT), Rod Biting Test (RBT), and locomotor activity. Biochemical analyses of TNF-α (plasma and amygdala) and serotonin (amygdala) were conducted using ELISA and HPLC. Treatment groups received either the TNF-α inhibitor etanercept, the IDO1 inhibitor minocycline, or both. BCG-inoculated mice exhibited increased aggression and reduced serotonin levels, alongside elevated TNF-α in the amygdala. Etanercept significantly reduced aggressive behavior and restored serotonin levels. Co-treatment with minocycline further enhanced these effects. Locomotor activity remained unchanged across all groups. TNF-α inhibition mitigates aggression by restoring serotonin levels, likely through suppression of IDO1 activity. Co-inhibition of IDO1 enhances this effect, highlighting the TNF-α/IDO1 pathway as a promising target for managing aggression.
Full text 107,137 characters · extracted from preprint-html · click to expand
Inhibition of the TNF-α/IDO1 Axis Restores Brain Serotonin and Mitigates Aggression-like Phenotypes in BCG-inoculated Mice | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Inhibition of the TNF-α/IDO1 Axis Restores Brain Serotonin and Mitigates Aggression-like Phenotypes in BCG-inoculated Mice Pooja R. Patil, Dhiraj D. Vispute, Sameer N. Goyal, Sanjay N. Awathale, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9174921/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Aggression is linked to systemic inflammation and serotonergic dysfunction. Tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine, disrupts serotonin synthesis by upregulating indoleamine 2,3-dioxygenase 1 (IDO1), which diverts tryptophan metabolism away from serotonin production. This study investigated whether inhibiting the TNF-α/IDO1 signaling pathway could reduce aggressive behavior. Aggression-like behaviors were induced in mice using Bacillus Calmette–Guérin (BCG), known to elevate systemic TNF-α and reduce brain serotonin. Behavioral assessments included the Social Aggression Test (SAT), Rod Biting Test (RBT), and locomotor activity. Biochemical analyses of TNF-α (plasma and amygdala) and serotonin (amygdala) were conducted using ELISA and HPLC. Treatment groups received either the TNF-α inhibitor etanercept, the IDO1 inhibitor minocycline, or both. BCG-inoculated mice exhibited increased aggression and reduced serotonin levels, alongside elevated TNF-α in the amygdala. Etanercept significantly reduced aggressive behavior and restored serotonin levels. Co-treatment with minocycline further enhanced these effects. Locomotor activity remained unchanged across all groups. TNF-α inhibition mitigates aggression by restoring serotonin levels, likely through suppression of IDO1 activity. Co-inhibition of IDO1 enhances this effect, highlighting the TNF-α/IDO1 pathway as a promising target for managing aggression. Aggression TNF-α IDO1 BCG Etanercept Minocycline Figures Figure 1 Figure 2 Figure 3 Figure 4 1. Introduction Aggression, characterized as hostile, injurious and destructive behavior, contributes to acts of violence that, according to the WHO, result in approximately 4.4 million deaths globally each year (Halvachizadeh et al. 2025). Mental disorders such as intermittent explosive disorder (IED) involve sudden, recurrent episodes of impulsive and disproportionate aggressive behavior in response to minor daily provocations (Liu and Yin 2024). Moreover, aggression can be triggered by a range of factors, including circadian rhythm disturbances, stress, hormonal fluctuations, experiences of victory or defeat, and comorbidity with certain psychological disorders (Lischinsky and Lin 2020). The aggressive behavior is modulated by a broad neural circuit involving several brain regions, including the amygdala (Rosell and Siever 2015; Blair 2016). Central serotonergic regulation of aggressive behavior is well documented, with the serotonin deficiency hypothesis of human aggression remaining the most widely supported hypothesis after decades of empirical testing (Duke et al. 2013). A polymorphism within an intron of the tryptophan hydroxylase (TPH) gene, which encodes the rate-limiting enzyme in serotonin synthesis, has been linked to aggressive behavior (Manuck et al. 1999). The efficacy of fluoxetine in treating IED by enhancing serotonergic neurotransmission supports the involvement of serotonin deficiency in the disorder (Liu and Yin 2024). The dorsal raphe nucleus is a primary source of serotonergic projections to several brain regions, including the prefrontal cortex, amygdala, hippocampus, striatum, and hypothalamus (Ren et al. 2019). Since serotonin promotes inhibition of the prefrontal cortex, reduced serotonergic activity increases the likelihood of aggression (Siever 2008). Notably, individuals exhibiting violent aggressive behavior have been found to show deficits in serotonergic transmission within the prefrontal cortex (Meyer et al. 2008). Further, the reduced serotonin levels in the prefrontal cortex-amygdala circuitry have been implicated in impulsive aggression (Passamonti et al. 2012). Aggression has been strongly linked to the inflammatory state in the body. Individuals with IED show elevated plasma inflammatory markers that correlate with aggression (Coccaro et al. 2014). Anger and interpersonal conflict can elevate cytokines such as TNF-α, especially in individuals displaying high hostility (Kiecolt-Glaser et al. 2005). Studies report a positive correlation between LPS-stimulated monocyte TNF-α expression and aggression in both males and females (Suarez et al. 2004). Similarly, T-cell-derived TNF-α levels are higher in individuals with greater hostility (Mommersteeg et al. 2008). Animal studies further support the immune system's involvement in aggression, as male mice lacking TNF receptors (TNF-R1 and TNF-R2) show reduced aggressive behavior in the resident-intruder test (Patel et al. 2010). Consistent with this, elevated TNF-α levels have been observed in highly aggressive individuals (Takahashi 2024). These data highlight the contributory role of inflammatory cytokines, particularly TNF-α, in aggressive behavior. It is important to note that peripheral TNF-α crosses the intact blood-brain barrier (BBB) through receptor-mediated transport mechanisms, which are upregulated under inflammatory conditions (Pan and Kastin 2007). In the brain, TNF-α activates the enzyme indoleamine 2,3 dioxygenase 1 (IDO1), which catabolizes tryptophan (serotonin precursor) into kynurenine, resulting in serotonin deficiency (Deore et al. 2024a; Sarangi 2024). These findings suggest that targeting TNF-α/IDO1 signaling can restore brain serotonin contents and suppress aggressive behavior. Our recent findings suggest a critical role of the amygdala in the regulation of aggressive behavior (Chaudhari et al. 2025a). In restrained animals, we observed elevated levels of pro-inflammatory cytokines, including TNF-α, as well as a reduction in serotonin levels within the amygdala. These neurochemical changes indicate that the amygdala may be a key neural substrate mediating aggression under stress-related conditions. However, the role of peripheral immune activation in modulating central mechanisms of aggression has not been fully explored. In this context, Bacillus Calmette–Guérin (BCG), a well-established immune activator and model for chronic immune stimulation, offers a valuable tool to investigate how peripheral immune challenges influence brain function and behavior. While BCG has been extensively studied in the context of depression-like behavior, its effect on aggression remains poorly characterized. Therefore, examining BCG-induced changes in aggressive behavior could provide novel insights into the neuroimmune pathways, particularly within the amygdala, that mediate aggression in response to immune stressors. In the present study, we aimed to evaluate the effects of TNF-α and IDO1 inhibition in a mouse model of BCG-induced aggressive-like behavior. Inoculation of BCG in mice has been shown to elevate plasma TNF-α levels, increase brain IDO1 expression, and decrease serotonin levels (Deore et al. 2024a). BCG-treated mice received TNF-α inhibitor etanercept, either alone or in combination with the IDO1 inhibitor minocycline. Aggressive behavior was assessed using the social aggression test (SAT), which involved monitoring attacks on an unfamiliar intruder, and the rod biting test (RBT), where restrained mice were observed for rod-directed biting behavior. Following behavioral testing, the concentration of the plasma and amygdalar TNF-α levels was measured using ELISA, and serotonin content in the amygdala was quantified using high-performance liquid chromatography (HPLC). Our findings revealed that BCG induced aggressive behavior, elevated TNF-α, and reduced brain serotonin levels. These behavioral and biochemical changes were attenuated by etanercept and further enhanced by co-administration with minocycline. 2. Materials and Methods 2.1. Animals Adult male Swiss Albino mice weighing about 30 g were housed in polypropylene cages at constant room temperature (25 ± 1°C), and relative humidity (50–70%), and fed on a 12:12 h light-dark cycle. All behavioral tests were performed between 9:00 a.m. and 2:00 p.m. Chow food pellets (Nutrivet Life Sciences, Pune, India) and water were given ad libitum . All experimental protocols were sanctioned by the Institutional Animal Ethics Committee (IAEC) of SVKM's Institute of Pharmacy, Dhule, Maharashtra, India (SVKM-IOP/IAEC/2024/December/05). 2.2. Drug preparations Commercial BCG preparation (Onco-BCG®, Serum Institute of India Pvt. Ltd., India) was used for the induction of aggressive-like phenotypes in mice. The vial contents were suspended in 4 mL saline to achieve a concentration of 10 9 CFU/mL (Vijaya Kumar et al. 2014). Commercially available injections of IDO1 inhibitor minocycline (Divaine®, Cipla Pharmaceuticals Ltd., India) and TNF-α inhibitor etanercept (Etacept®, Cipla Pharmaceuticals Ltd., India) were used. Lyophilized powder of etanercept was reconstituted with water for injection. 2.3. Experimental design The mice were assigned randomly to various groups (n = 6). BCG was inoculated (0.225 mL/mouse) via the intraperitoneal (i.p.) route on day 1 of the study, and housed individually. Then the animals received various treatments from days 15–21 as stated below. Alongside, saline was administered to the control group. Group I : Control Group II : BCG (Disease control) Group III : BCG → Etanercept (1.5 mg/kg, s.c.) Group IV : BCG → Etanercept (3 mg/kg, s.c.) Group V : BCG → Minocycline (25 mg/kg, i.p.) Group VI : BCG → Minocycline (25 mg/kg, i.p.) + Etanercept (1.5 mg/kg, s.c.) Group VII : BCG → Minocycline (25 mg/kg, i.p.) + Etanercept (3 mg/kg, s.c.) On day 21, animals were subjected to behavioral studies followed by biochemical analysis of blood and brain samples. The experimental protocol is outlined in Fig. 1 . 2.4. Behavioral Assessments Social Aggression Test (SAT) : Attacking behavior towards an unfamiliar partner permits the measurement of reactive aggression. In this test, unfamiliar male mice were introduced into the home cages of the test mice. The unfamiliar partners were at least weighing 5 g less than the test animals (e.g., 25 g vs 30 g). The reactive aggressive behavior, i.e., the physical attack exhibited by the test mouse against an unfamiliar partner mouse, was monitored for 5 minutes. Once the experiment finished, the unfamiliar mouse was returned to its home cage (Kim et al. 2017). The interaction video was recorded from above using cameras, and the quantification of aggressive biting behavior was assessed. Rod Biting Test (RBT) : The restraint-induced aggressive behavior in rodents has been validated in our laboratory (Chaudhari et al. 2025a). In this test, mouse was placed in the in-house fabricated restrainer for 5 minutes. Subsequently, a removable metal rod (4 cm in length and 5 mm in diameter) was inserted at the end of the restrainer, positioned near the animal's nose. The rod was consisted of two parallel metals connected to an electrical circuit and a counter. When animal bites the rod, the electric circuit completed and number of bites were recorded. The number of rod bites by the restrained mouse was counted for 3 minutes and used as an index of IED (Kuchiiwa and Kuchiiwa 2014). Open field test (OFT) To test the effect of various treatments on locomotor activity, the OFT was conducted based on protocols from earlier research (Deore et al. 2024b; Awathale et al. 2025; Shirasath et al. 2025). The OFT apparatus (50 × 50 × 20 cm) was equipped with invisible vertical and parallel infrared (IR) beams connected to an actimeter system. Each mouse was individually placed at the center of the arena and observed for 5 minutes. Locomotor activity was automatically recorded by counting the number of IR beam interruptions, expressed as actimeter counts. To eliminate residual odors, the arena was cleaned with 70% alcohol after each trial. Blood sample collection Immediately after RBT, all the mice from control, diseased and treatment groups (Groups I to VII) were deeply anesthetized by overdose of thiopentone sodium (75 mg/kg; i.p.). The blood samples were collected by retro-orbital puncture in EDTA tubes. Blood samples were centrifuged at 10000xg for 15 min at 4°C. The plasma supernatant was collected, and the levels of TNF-α were determined using ELISA kits. 2.5. Preparation tissue homogenate After completion of the behavioral assessment and blood withdrawal, mice from various experimental groups [(saline, BCG, BCG + etanercept (3 mg/kg) and BCG + etanercept (3 mg/kg) + minocycline (25 mg/kg)] were sacrificed using thiopentone sodium (75 mg/kg, ip), the brains were isolated and kept at -80°C. Amygdala from both hemispheres were separated using a biopsy punch (2 mm diameter). Tissues were homogenized in 500 µl 0.1 N perchloric acid and centrifuged at 10000×g for 5 min at 4°C. Tissue samples were taken from coronal brain sections spanning bregma coordinates − 2.12 mm to -2.80 mm, based on the rat brain atlas by Paxinos and Watson (1998), to maintain anatomical consistency among all subjects. The collected tissue was then homogenized in ice-cold PBS at pH 7.5. The resulting homogenate was transferred to Eppendorf tubes and centrifuged at 10000xg at 0°C for 10 minutes. The supernatant was then collected and stored at -20°C for further analysis. (Deore et al. 2024b; Pardeshi et al. 2025; Awathale et al. 2025; Chaudhari et al. 2025a). Half of the supernatant was utilized for ELISA, and the remaining was used for HPLC analysis. 2.6. Determination of concentration of TNF-α in the plasma and the amygdala For the determination of plasma TNF-α, 100 µL of the plasma samples and standards were added to a 96-well plate in triplicate. The total protein content in the supernatant of the amygdala was measured using the bicinchoninic acid (BCA) assay. Protein concentrations were then adjusted to 1 µg/µL using PBS. Each tissue sample (100 µL, equivalent to 100 µg of protein) was loaded in triplicate into a 96-well plate along with the standards. The concentrations of TNF-α in the plasma and amygdala were quantified following the manufacturer’s instructions mentioned in the ELISA kits (Cat No. ELK1396, ELK Biotechnology Co. Ltd., USA) (Pardeshi et al. 2025; Chaudhari et al. 2025b). 2.7. Measurement of serotonin in the amygdala by using high-performance liquid chromatography (HPLC) The method of HPLC was adopted from our previous studies (Deore et al. 2024a; Pardeshi et al. 2025; Chaudhari et al. 2025a). The supernatant was removed and filtered through a nylon filter (22 µm), again centrifuged at 12,000 rpm for 5 min at 4°C (O’Connor et al. 2009). The supernatant was removed and diluted with 0.02 N perchloric acid at a 1:100 ratio (v:v). These samples were injected into the HPLC system for the determination of serotonin (O’Connor et al. 2009; Awathale et al. 2020). Serotonin levels in the tissue homogenate were analyzed by HPLC using a photodiode array detector, and the isocratic reverse phase-HPLC was performed on Sunfire C18 column (250 mm × 4.6 mm, 5 µm). The mobile phases consisted of potassium dihydrogen phosphate (KH 2 PO 4 )/acetonitrile (90:10 v/v). The flow rate was maintained at 1.0 mL/min, and the run time was 8 min. Serotonin content in the amygdala was analyzed at + 320 mV. The injection volume (20 µl) of tissue homogenate was injected into the HPLC system. The retention time (RT) of each sample peak was recorded and compared with the RT of the external standard of serotonin (Sigma, USA; Cat No. H9523) prepared in 0.02 N perchloric acid. The area under the curve (AUC) of each chromatogram was quantified using Empower 3 software (Waters Instrument) and expressed as mean ± standard error of the mean (SEM) (Awathale et al. 2020). 2.8. Statistical analysis The data are represented as mean ± SEM. The statistical analysis of the data was performed by one-way ANOVA, followed by post-hoc Bonferroni’s multiple comparisons tests using GraphPad Prism software. The normal distribution of data was calculated by using the online calculator present at the Statistics Kingdom website ( https://www.statskingdom.com/shapiro-wilk-test-calculator.html ); all the data were found to be normally distributed. Applications of Grubbs’ test revealed no outliers across the data. The data was considered significant if p < 0.05. 3. Results 3.1. Effect of etanercept on SAT, and its modulation by minocycline in BCG-inoculated mice The effect of BCG inoculation on the aggressive behavior of test mice with unfamiliar mice was screened using SAT. Further, the effects of etanercept, alone and jointly with minocycline, were screened. Application of one-way ANOVA showed a significant change in the number of attacks within different groups of mice [F (6, 35) = 54.04, p < 0.0001, Fig. 2A]. Post-hoc Bonferroni’s multiple comparisons test revealed a significant elevation in the number of attacks in BCG- inoculated mice as compared to the control (p 0.05) and at the 3 mg/kg dose decreased the number of attacks as compared to the disease control (p 0.05). Interestingly, its combination with a subeffective dose of etanercept (1.5 mg/kg) resulted in a significant decrease in the number of attacks as compared to disease control (p < 0.0001) and etanercept alone at 1.5 mg/kg (p < 0.01). Likewise, minocycline potentiated the effect of etanercept (3 mg/kg) and significantly decreased the number of attacks as compared to the BCG only (p < 0.0001) and etanercept alone (p < 0.001) (Fig. 2A). 3.2. Effect of etanercept on RBT, and its modulation by minocycline in BCG-inoculated mice Application of one-way ANOVA showed a significant change in the number of bites within different groups of mice [F (6, 35) = 148.9, p < 0.0001, Fig. 2B]. Post-hoc Bonferroni’s multiple comparisons test revealed that the number of Bites was increased in BCG-inoculated mice as compared to the control (p 0.05) and at the 3 mg/kg dose decreased the number of Bites as compared to the disease control (p 0.05). Interestingly, its combination with a subeffective dose of etanercept (1.5 mg/kg) resulted in a significant decrease in the number of Bites as compared to disease control (p < 0.0001) and per se treatment of etanercept (1.5 mg/kg) (p < 0.0001). Likewise, minocycline significantly potentiated the effect of etanercept (3 mg/kg) and decreases the number of Bites as compared disease control (p < 0.0001) and etanercept alone (3 mg/kg) (p < 0.01) (Fig. 2B). Although per se treatment with minocycline (25 mg/kg) or etanercept (1.5 mg/kg) failed to show a noticeable effect on Aggressive Biting behavior, a non-significantly decreased number of bites were observed (p > 0.05) as compared to disease control. This suggests that the combination of minocycline and etanercept reduces aggressive behavior through IDO1 and TNF-α inhibition. These data reflect that there is functional synergism between etanercept and minocycline with respect to aggressive behavior. 3.3. Effect of etanercept on locomotor activity, and its modulation by minocycline in BCG-inoculated mice The effect of etanercept and minocycline on locomotor activity using OFT in different groups of mice. The data were analyzed by one-way ANOVA revealed no significant changes in locomotor count among all experimental groups [F (6, 35) = 99.44, p = 0.4443, Fig. 2C]. The post-hoc analysis using Bonferroni’s multiple comparisons test demonstrated no significant alterations in locomotor activity among all groups of animals (p > 0.05). These results indicate that neither etanercept nor its combination with minocycline affects locomotor activity, thereby ruling out any cofounding influence of locomotion on the aggressive behavior with unfamiliar mice and with rod activity. 3.4. Effect of etanercept on TNF-α concentration in the plasma and amygdala of mice with aggressive-like behavior, and their modulation by minocycline The concentrations of pro-inflammatory marker, TNF-α, in BCG-treated mice with etanercept (1.5 and 3 mg/kg), alone and in combination with minocycline (25 mg/kg), were determined in plasma using ELISA. Application of one-way ANOVA showed a significant variation in the plasma concentration of TNF-α among the different groups of mice [F (6, 35) = 97.14, p < 0.0001, Fig. 3A] and in amygdala [F (6, 35) = 14.88, p < 0.0001, Fig. 3B]. Post-hoc Bonferroni's multiple comparisons test revealed a significant increase in the concentrations of plasma and amygdala TNF-α in the BCG-treated mice as compared to the control (both p < 0.001), indicating that BCG increases pro-inflammatory cytokine concentration in periphery as well as in brain (amygdala). Subeffective dose of etanercept (1.5 mg/kg) shows a non-significant decrease in the level of TNF-α in plasma (Fig. 3A) and amygdala (Fig. 3B) as compared to disease control mice (p > 0.05). Moreover, effective dose of etanercept (3 mg/kg) decreases the level of TNF-α in plasma and amygdala as compared to disease control mice (both p 0.05). Co-administration of etanercept (1.5 mg/kg) with minocycline (25 mg/kg) further reduced the TNF-α content in plasma (p < 0.05) and amygdala (p < 0.01). However, minocycline potentiated the effect of etanercept (3 mg/kg) (p < 0.001) and significantly decreased plasma and amygdala TNF-α level as compared to etanercept alone both (p < 0.001) (Fig. 3A and B). This suggests that minocycline potentiated the effect of etanercept and significantly reduced plasma and amygdala TNF-α level, which was accompanied by alleviating the aggression-like phenotype in mice. 3.5. Effect of BCG, etanercept and their combination with minocycline on levels of serotonin in the mice brain The effect of etanercept and combination with minocycline on the brain serotonin levels was determined using HPLC systems. Application of one-way ANOVA showed significant alteration in the levels of serotonin [chromatograms in Fig. 4A–E; AUC, F (3, 20) = 1471, p < 0.0001, Fig. 4E]. Post-hoc Bonferroni’s multiple comparisons test revealed that the AUC of the 5-HT were significantly decreased in the BCG-injected mice as compared to control (p < 0.001, Fig. 4E). However, etanercept at the dose of 3 mg/kg significantly increased the AUC of serotonin as compared to the disease control mice (p < 0.001, Fig. 4E). Furthermore, etanercept (3 mg/kg) in combination with minocycline (25 mg/kg) significantly increased the AUC of the serotonin as compared to the disease control mice and etanercept alone (p < 0.0001, Fig. 4E). These data indicate that BCG lowers the levels of serotonin which may be contributed to the induction of Aggressive behavior in mice. Moreover, the injection of etanercept alone and in combination with minocycline improves the levels of 5-HT, suggesting its alleviating aggressive behavior that might be associated with the modulation of the TNF-α receptor and IDO1 enzyme. 4. Discussion Aggression can be induced by a number of risk factors, including biological and psychological, for example, genetics and mental illnesses, and socioeconomic (Fritz et al. 2023). The current study investigated the mechanisms through which BCG-induced systemic inflammation and influences aggression-like behavior in mice and examined the therapeutic potential of etanercept, a TNF-α inhibitor, and minocycline, an IDO1 inhibitor, alone and in combination. One of the key outcomes of this research is the development of BCG-induced aggression as a reproducible and stable model to investigate the effects of chronic neuroinflammation on behavior. BCG immunization robustly enhanced aggressive-like behaviors in the SIT and RBT. These behavioral modifications were accompanied by biochemical changes in proinflammatory cytokines and serotonin content, highlighting the neuroimmune connection in aggression. Pathological aggression levels in intermittent IED or psychosis seem to be associated with increased proinflammatory cytokines (Bhatt et al. 2008; Das et al. 2016). Our results support the perspective that immune system activation is important in the modulation of behavioral states. The BCG vaccine, although conventionally employed as a protective measure against tuberculosis, is recognized to cause systemic immune activation. In our research, it robustly increased plasma TNF-α levels, an important cytokine that affects CNS function and is frequently involved in mood and behavioral disorders. In dendritic cells TNF-α activate the JAK/STAT pathway & these stimuli result in IDO1 activation (Manches et al. 2012). Blood-brain barrier endothelial cells utilize IDO1 for the degradation of tryptophan into kynurenine for the maintenance of their function (Adam et al. 2005). L-tryptophan is not only a building block of proteins but also a precursor to serotonin synthesis (Comai et al. 2020). However, the major metabolic pathway of L-tryptophan is the catabolic pathway catalyzed by IDO1 enzyme that converts L-tryptophan to kynurenine and its metabolites, especially in inflammatory states (Badawy 2017; Pallotta et al. 2022). Under conditions of inflammation, over 95% of free L-tryptophan can be catabolized via the kynurenine pathway. In the present investigation, mice subjected to restraint stress showed elevated TNF-α concentration in the amygdala, associated with defensive rage (Pesce et al. 2011). The role of the central amygdala in the pathology of aggression and violence has been well documented (Haller 2018). Maternal separation-induced aggression triggers a higher activation of the amygdala (Ohta et al. 2023). Therefore, in the present investigation, the involvement of TNF-α of the amygdala in the regulation of aggressive phenotype was tested. While restraint stress equipped with a biting rod elevates TNF-α in the amygdala, etanercept alone and in combination with minocycline significantly reduces its level. These results demonstrated that antagonism of the TNF-α-IDO1 interaction in the amygdala might have a regulatory effect on aggressive biting behavior in BCG-inoculated mice. Whereas IDO1 activation in neuroinflammation induces serotonin production deficiency that can in-turn trigger psychiatric diseases (Jeon and Kim 2017). Dysregulation of the serotonin system has been implicated in the hyperexpression of aggression (Miczek et al. 2007). In line with this, our HPLC results indicated a marked reduction in brain serotonin levels in BCG-inoculated mice as compared to controls, which supports the mechanistic pathway of systemic inflammation leading to modified serotonergic signaling. The behavioral effects showed that etanercept, especially at a higher dose of 5 mg/kg, highly decreased aggressive behaviors in both tests. This indicates that inhibition of TNF-α signaling alone is enough to weaken some of the effects of BCG for inducing aggression. Interestingly, although minocycline alone had a non-significant effect, a combination of it with a sub-effective and effective dose of etanercept was highly effective in reducing aggression. This suggests that there is a synergistic interaction between TNF-α and IDO1 pathways in controlling aggression. Combined treatment perhaps has dual inhibition preventing the release of pro-inflammatory cytokines and inhibiting tryptophan catabolism, thus maintaining serotonin levels and mood and behavioral stabilization. This observation fits with the wider context of neuroimmune communication, in which cytokines and immune-activated enzymes communicate with neurotransmitter systems to have an effect on behavior. Stress-induced increased peripheral inflammation modulates BBB permeability, facilitating infiltration of freely circulating inflammatory factors into mood‐associated brain regions' parenchyma, leading to damage and neural circuit modification (Miller and Raison 2016; Menard et al. 2017; Beurel et al. 2020). Inflammatory stimuli were found to affect brain areas associated with emotional processing, such as the amygdala (Anisman et al. 2008; Mehta et al. 2022). The amygdala is the core of a neural system that deals with affective stimulus, particularly negatively valenced stimulus and aggression (Singh and Gobrogge 2024; Chaudhari et al. 2025b). Violent criminals have lower levels of serotonin than do nonviolent criminals, and criminals convicted of impulsive violent crimes have lower serotonin levels than criminals convicted of premeditated crimes (Virkkunen et al. 1987). So, the decreased serotonin in our BCG-injected mice probably caused this imbalance, impairing behavioral inhibition and increasing reactivity to provocation. In addition, our research provides a translational perspective through the employment of clinical agents, pharmacologically available etanercept and minocycline. Etanercept, a biologic inhibitor of TNF have since been clinically effective in lowering inflammation related to a number of autoimmune disorders, including rheumatoid arthritis, psoriasis and Crohn's disease (Croft et al. 2024). It exhibits a significant effect on the inhibition of inflammation (Li et al. 2022). Minocycline is a tetracycline antibiotic with extensive anti-inflammatory effects and excellent central nervous system penetration. Thus, it has anti-inflammatory and neuroprotective effects and has been investigated for mood disorders as well as in other psychiatric diseases like bipolar disease and schizophrenia (Nettis 2021). The efficacy of these agents in suppressing aggression in our model suggests their potential for repurposing towards the treatment of neuroinflammation-related behavioral disorders. 5. Conclusion The cytokine model of depression suggests that raised levels of proinflammatory cytokines including IL-6 and TNF-α, may be involved in the etiology of depressive symptoms and influence mood regulation and play a role in the episodic nature of the disorder. Neuroinflammation may interfere with neurotransmitter systems involved in depression, such as serotonin, dopamine, and glutamate (Levin 2024). Moreover, high states of anger (acute episodes of anger) also induce proinflammatory cytokine release (Kiecolt-Glaser et al. 2005). A modulating function of cytokines in mammalian aggressive behavior is implicated by direct experimental manipulation in lower mammals (Zalcman and Siegel 2006; Bhatt et al. 2008; Coccaro et al. 2015), by inflammatory cytokines' effect on anger and aggression in patients undergoing cytokine immunotherapy (McHutchison et al. 1998; Kraus et al. 2003). It is also noteworthy that the above data support the cytokine theory of affective disorders, which posits that elevated levels of proinflammatory cytokines can influence mood, behavior, and emotional regulation, thereby contributing to increased anger and aggression. Declarations Acknowledgements Kartik T. Nakhate acknowledges the Indian Council of Medical Research (ICMR), Government of India, New Delhi (Ad-hoc Project ID: 2021–11133) and SEED Grant SVKM’s Institute of Pharmacy, Dhule, MH, India for research funding (Grant No. SVKM/IOP/ 2023–24/1303H). CRediT authorship contribution statement Pooja Patil and Dhiraj Vispute : Conceptualization, Writing-original draft, Methodology, Formal analysis, Investigation, Writing-review & editing, Visualization. Sameer N. Goyal: Writing-review & editing, Validation, Resources, Formal analysis, Funding acquisition. Sanjay Awathale and Kartik T. Nakhate: Conceptualization, Methodology, Supervision, Writing-review & editing, Visualization, Validation, Investigation, Formal analysis, Project administration. All authors reviewed the results and approved the final manuscript version. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Funding Declaration This study was supported by the Indian Council of Medical Research (ICMR), Government of India, New Delhi (Ad-hoc Project ID: 2021–11133) and SEED Grant SVKM’s Institute of Pharmacy, Dhule, MH, India for research funding (Grant No. SVKM/IOP/ 2023–24/1303H). Data availability statement Data will be made available on request. References Adam R, Rüssing D, Adams O, et al (2005) Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb Haemost 94:341–346. https://doi.org/10.1160/TH05-01-0053 Anisman H, Merali Z, Hayley S (2008) Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Progress in Neurobiology 85:1–74. https://doi.org/10.1016/j.pneurobio.2008.01.004 Awathale SN, Dudhbhate BB, Rahangdale RR, et al (2020) Denial of food to the hungry rat: a novel paradigm for induction and evaluation of anger-like emotion. Journal of Neuroscience Methods 341:108791 Awathale SN, Shirasath KR, More BR, et al (2025) Naringenin prevents ethanol-induced reward behavior in adolescent rats through inhibition of TRPM3-dependent inflammation in the pVTA. J Nutr Biochem 110078. https://doi.org/10.1016/j.jnutbio.2025.110078 Badawy AA-B (2017) Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res 10:1178646917691938. https://doi.org/10.1177/1178646917691938 Beurel E, Toups M, Nemeroff CB (2020) The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 107:234–256. https://doi.org/10.1016/j.neuron.2020.06.002 Bhatt S, Bhatt R, Zalcman SS, Siegel A (2008) Role of IL-1 beta and 5-HT2 receptors in midbrain periaqueductal gray (PAG) in potentiating defensive rage behavior in cat. Brain Behav Immun 22:224–233. https://doi.org/10.1016/j.bbi.2007.07.011 Blair RJR (2016) The Neurobiology of Impulsive Aggression. J Child Adolesc Psychopharmacol 26:4–9. https://doi.org/10.1089/cap.2015.0088 Chaudhari AK, Shirasath KR, Goyal SN, et al (2025a) A novel biting rod model for assessing aggressive behavior in restraint-stressed rats: Role of 5-HT3 receptor and NF-κB-kynurenine pathways. Physiol Behav 115091. https://doi.org/10.1016/j.physbeh.2025.115091 Coccaro EF, Lee R, Coussons-Read M (2014) Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. JAMA Psychiatry 71:158–165. https://doi.org/10.1001/jamapsychiatry.2013.3297 Coccaro EF, Lee R, Coussons-Read M (2015) Cerebrospinal Fluid Inflammatory Cytokines and Aggression in Personality Disordered Subjects. Int J Neuropsychopharmacol 18:pyv001. https://doi.org/10.1093/ijnp/pyv001 Comai S, Bertazzo A, Brughera M, Crotti S (2020) Chapter Five - Tryptophan in health and disease. In: Makowski GS (ed) Advances in Clinical Chemistry. Elsevier, pp 165–218 Croft M, Salek-Ardakani S, Ware CF (2024) Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov 23:939–961. https://doi.org/10.1038/s41573-024-01053-9 Das S, Deuri SK, Sarmah A, et al (2016) Aggression as an independent entity even in psychosis- the role of inflammatory cytokines. Journal of Neuroimmunology 292:45–51. https://doi.org/10.1016/j.jneuroim.2016.01.012 Deore R, Ansari R, Awathale SN, et al (2024a) Lycopene alleviates BCG-induced depressive phenotypes in mice by disrupting 5-HT3 receptor - IDO1 interplay in the brain. Eur J Pharmacol 977:176707. https://doi.org/10.1016/j.ejphar.2024.176707 Duke AA, Bègue L, Bell R, Eisenlohr-Moul T (2013) Revisiting the serotonin-aggression relation in humans: a meta-analysis. Psychol Bull 139:1148–1172. https://doi.org/10.1037/a0031544 Fritz M, Soravia S-M, Dudeck M, et al (2023) Neurobiology of Aggression—Review of Recent Findings and Relationship with Alcohol and Trauma. Biology (Basel) 12:469. https://doi.org/10.3390/biology12030469 Haller J (2018) The role of central and medial amygdala in normal and abnormal aggression: A review of classical approaches. Neuroscience & Biobehavioral Reviews 85:34–43. https://doi.org/10.1016/j.neubiorev.2017.09.017 Halvachizadeh S, Mariani D, Pfeifer R (2025) Impact of trauma on society. Eur J Trauma Emerg Surg 51:155. https://doi.org/10.1007/s00068-025-02824-8 Jeon SW, Kim Y-K (2017) Inflammation-induced depression: Its pathophysiology and therapeutic implications. J Neuroimmunol 313:92–98. https://doi.org/10.1016/j.jneuroim.2017.10.016 Kiecolt-Glaser JK, Loving TJ, Stowell JR, et al (2005) Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry 62:1377–1384. https://doi.org/10.1001/archpsyc.62.12.1377 Kim H-D, Call T, Carotenuto S, et al (2017) Testing Depression in Mice: a Chronic Social Defeat Stress Model. Bio Protoc 7:e2203. https://doi.org/10.21769/BioProtoc.2203 Kraus MR, Schäfer A, Faller H, et al (2003) Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64:708–714. https://doi.org/10.4088/jcp.v64n0614 Kuchiiwa S, Kuchiiwa T (2014) A novel semi-automated apparatus for measurement of aggressive biting behavior in mice. J Neurosci Methods 228:27–34. https://doi.org/10.1016/j.jneumeth.2014.02.017 Levin M (2024) The Role of Neuroinflammation in Psychiatric Disorders. Neuroscience and Psychiatry: Open Access 7:265–267. https://doi.org/10.47532/npoa.2024.7(5).265-267 Li Y, Fan H, Ni M, et al (2022) Etanercept Reduces Neuron Injury and Neuroinflammation via Inactivating c-Jun N-terminal Kinase and Nuclear Factor-κB Pathways in Alzheimer’s Disease: An In Vitro and In Vivo Investigation. Neuroscience 484:140–150. https://doi.org/10.1016/j.neuroscience.2021.11.001 Lischinsky JE, Lin D (2020) Neural mechanisms of aggression across species. Nat Neurosci 23:1317–1328. https://doi.org/10.1038/s41593-020-00715-2 Liu F, Yin X (2024) Psychological and pharmacological treatments of intermittent explosive disorder: a meta-analysis protocol. BMJ Open 14:e083896. https://doi.org/10.1136/bmjopen-2024-083896 Manches O, Fernandez MV, Plumas J, et al (2012) Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci U S A 109:14122–14127. https://doi.org/10.1073/pnas.1204032109 Manuck SB, Flory JD, Ferrell RE, et al (1999) Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. Biol Psychiatry 45:603–614. https://doi.org/10.1016/s0006-3223(98)00375-8 McHutchison JG, Gordon SC, Schiff ER, et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485–1492. https://doi.org/10.1056/NEJM199811193392101 Mehta ND, Stevens JS, Li Z, et al (2022) Inflammation, Amygdala-Ventromedial Prefrontal Functional Connectivity and Symptoms of Anxiety and PTSD in African American Women Recruited from an Inner-City Hospital: Preliminary Results. Brain Behav Immun 105:122–130. https://doi.org/10.1016/j.bbi.2022.06.013 Menard C, Pfau ML, Hodes GE, et al (2017) Social stress induces neurovascular pathology promoting depression. Nat Neurosci 20:1752–1760. https://doi.org/10.1038/s41593-017-0010-3 Meyer JH, Wilson AA, Rusjan P, et al (2008) Serotonin2A receptor binding potential in people with aggressive and violent behaviour. J Psychiatry Neurosci 33:499–508 Miczek KA, de Almeida RMM, Kravitz EA, et al (2007) Neurobiology of escalated aggression and violence. J Neurosci 27:11803–11806. https://doi.org/10.1523/JNEUROSCI.3500-07.2007 Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34. https://doi.org/10.1038/nri.2015.5 Mommersteeg PMC, Vermetten E, Kavelaars A, et al (2008) Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 33:1041–1050. https://doi.org/10.1016/j.psyneuen.2008.05.007 Nettis MA (2021) Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders. Brain Behav Immun Health 17:100335. https://doi.org/10.1016/j.bbih.2021.100335 O’Connor JC, André C, Wang Y, et al (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29:4200–4209. https://doi.org/10.1523/JNEUROSCI.5032-08.2009 Ohta K, Araki C, Ujihara H, et al (2023) Maternal separation early in life induces excessive activity of the central amygdala related to abnormal aggression. Journal of Neurochemistry 167:778–794. https://doi.org/10.1111/jnc.16020 Pallotta MT, Rossini S, Suvieri C, et al (2022) Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme. FEBS J 289:6099–6118. https://doi.org/10.1111/febs.16086 Pan W, Kastin AJ (2007) Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 83:363–374. https://doi.org/10.1016/j.pneurobio.2007.07.008 Pardeshi GN, Ali N, Shirasath KR, et al (2025) Inhibition of TRPM3 channels in the medial prefrontal cortex mitigates OCD symptoms following traumatic brain injury. Inflammopharmacol. https://doi.org/10.1007/s10787-025-01763-5 Passamonti L, Crockett MJ, Apergis-Schoute AM, et al (2012) Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. Biol Psychiatry 71:36–43. https://doi.org/10.1016/j.biopsych.2011.07.033 Patel A, Siegel A, Zalcman SS (2010) Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav Immun 24:1276–1280. https://doi.org/10.1016/j.bbi.2010.05.005 Pesce M, Speranza L, Franceschelli S, et al (2011) Biological role of interleukin-1beta in defensive-aggressive behaviour. J Biol Regul Homeost Agents 25:323–329 Ren J, Isakova A, Friedmann D, et al (2019) Single-cell transcriptomes and whole-brain projections of serotonin neurons in the mouse dorsal and median raphe nuclei. eLife 8:e49424. https://doi.org/10.7554/eLife.49424 Rosell DR, Siever LJ (2015) The neurobiology of aggression and violence. CNS Spectr 20:254–279. https://doi.org/10.1017/S109285291500019X Sarangi P (2024) Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer. Cancer Pathogenesis and Therapy 2:246–255. https://doi.org/10.1016/j.cpt.2023.11.001 Shirasath KR, Chaudhari AK, Nakhate KT, et al (2025) Plumbagin Alleviates Mild Traumatic Brain Injury-Induced Obsessive-Compulsive Disorder in Mice by Inhibiting nNOS and Augmenting Cortico-Striatal Serotonin Levels. Phytother Res. https://doi.org/10.1002/ptr.70105 Siever LJ (2008) Neurobiology of Aggression and Violence. Am J Psychiatry 165:429–442. https://doi.org/10.1176/appi.ajp.2008.07111774 Singh R, Gobrogge K (2024) Aggression Unleashed: Neural Circuits from Scent to Brain. Brain Sci 14:794. https://doi.org/10.3390/brainsci14080794 Suarez EC, Lewis JG, Krishnan RR, Young KH (2004) Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 29:1119–1128. https://doi.org/10.1016/j.psyneuen.2004.01.002 Takahashi A (2024) Associations of the immune system in aggression traits and the role of microglia as mediators. Neuropharmacology 256:110021. https://doi.org/10.1016/j.neuropharm.2024.110021 Vijaya Kumar K, Rudra A, Sreedhara MV, et al (2014) Bacillus Calmette-Guérin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice. Brain Behav Immun 42:204–211. https://doi.org/10.1016/j.bbi.2014.06.205 Virkkunen M, Nuutila A, Goodwin FK, Linnoila M (1987) Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry 44:241–247. https://doi.org/10.1001/archpsyc.1987.01800150053007 Zalcman SS, Siegel A (2006) The neurobiology of aggression and rage: role of cytokines. Brain Behav Immun 20:507–514. https://doi.org/10.1016/j.bbi.2006.05.002 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9174921","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":611213352,"identity":"45b8292a-0bd7-4c36-a533-084f821aa988","order_by":0,"name":"Pooja R. Patil","email":"","orcid":"","institution":"SVKM NMIMS Global University","correspondingAuthor":false,"prefix":"","firstName":"Pooja","middleName":"R.","lastName":"Patil","suffix":""},{"id":611213354,"identity":"67e32ac6-d6f9-45d5-9306-0c58836bd3e4","order_by":1,"name":"Dhiraj D. Vispute","email":"","orcid":"","institution":"SVKM NMIMS Global University","correspondingAuthor":false,"prefix":"","firstName":"Dhiraj","middleName":"D.","lastName":"Vispute","suffix":""},{"id":611213360,"identity":"3d54c448-2585-4114-a402-00ad2e334836","order_by":2,"name":"Sameer N. Goyal","email":"","orcid":"","institution":"SVKM NMIMS Global University","correspondingAuthor":false,"prefix":"","firstName":"Sameer","middleName":"N.","lastName":"Goyal","suffix":""},{"id":611213362,"identity":"e3738da0-b5b0-408e-a639-c4be24546313","order_by":3,"name":"Sanjay N. Awathale","email":"data:image/png;base64,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","orcid":"","institution":"SVKM NMIMS Global University","correspondingAuthor":true,"prefix":"","firstName":"Sanjay","middleName":"N.","lastName":"Awathale","suffix":""},{"id":611213364,"identity":"e88c773a-91c6-498c-a6ff-b87663b7f3cb","order_by":4,"name":"Kartik T. Nakhate","email":"","orcid":"","institution":"SVKM NMIMS Global University","correspondingAuthor":false,"prefix":"","firstName":"Kartik","middleName":"T.","lastName":"Nakhate","suffix":""}],"badges":[],"createdAt":"2026-03-20 04:55:13","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-9174921/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9174921/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":105403490,"identity":"e41d603c-9d00-43dc-805e-c63991b0f422","added_by":"auto","created_at":"2026-03-25 15:53:01","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":309208,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version\u003c/p\u003e","description":"","filename":"Fig.1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-9174921/v1/e580880a107db09bc35c0415.jpg"},{"id":105403489,"identity":"54fe5303-9e0c-46b0-b74f-a6e0f60930c6","added_by":"auto","created_at":"2026-03-25 15:53:01","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":80665,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version\u003c/p\u003e","description":"","filename":"Fig.2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-9174921/v1/8e912f40bd8f1e21afebb584.jpg"},{"id":105403488,"identity":"818f4c94-dc03-499b-bcde-9acb21b4603d","added_by":"auto","created_at":"2026-03-25 15:53:01","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":98791,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version\u003c/p\u003e","description":"","filename":"Fig.3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-9174921/v1/f8d63c69a0deab29fe934bf6.jpg"},{"id":105403491,"identity":"09560ccf-7420-4cda-bd50-eda7a1687ebc","added_by":"auto","created_at":"2026-03-25 15:53:01","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":138813,"visible":true,"origin":"","legend":"\u003cp\u003eLegend not included with this version\u003c/p\u003e","description":"","filename":"Fig.4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-9174921/v1/ad4688c43ad5cc03a40bf876.jpg"},{"id":105565661,"identity":"d5b29a21-3975-43a8-b0f0-9685e5cbc473","added_by":"auto","created_at":"2026-03-27 12:53:57","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1486905,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9174921/v1/7e95fbc1-abd8-4f1a-8ac6-152eba23f930.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Inhibition of the TNF-α/IDO1 Axis Restores Brain Serotonin and Mitigates Aggression-like Phenotypes in BCG-inoculated Mice","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eAggression, characterized as hostile, injurious and destructive behavior, contributes to acts of violence that, according to the WHO, result in approximately 4.4\u0026nbsp;million deaths globally each year (Halvachizadeh et al. 2025). Mental disorders such as intermittent explosive disorder (IED) involve sudden, recurrent episodes of impulsive and disproportionate aggressive behavior in response to minor daily provocations (Liu and Yin 2024). Moreover, aggression can be triggered by a range of factors, including circadian rhythm disturbances, stress, hormonal fluctuations, experiences of victory or defeat, and comorbidity with certain psychological disorders (Lischinsky and Lin 2020). The aggressive behavior is modulated by a broad neural circuit involving several brain regions, including the amygdala (Rosell and Siever 2015; Blair 2016). Central serotonergic regulation of aggressive behavior is well documented, with the \u003cem\u003eserotonin deficiency hypothesis\u003c/em\u003e of human aggression remaining the most widely supported hypothesis after decades of empirical testing (Duke et al. 2013). A polymorphism within an intron of the tryptophan hydroxylase (TPH) gene, which encodes the rate-limiting enzyme in serotonin synthesis, has been linked to aggressive behavior (Manuck et al. 1999). The efficacy of fluoxetine in treating IED by enhancing serotonergic neurotransmission supports the involvement of serotonin deficiency in the disorder (Liu and Yin 2024). The dorsal raphe nucleus is a primary source of serotonergic projections to several brain regions, including the prefrontal cortex, amygdala, hippocampus, striatum, and hypothalamus (Ren et al. 2019). Since serotonin promotes inhibition of the prefrontal cortex, reduced serotonergic activity increases the likelihood of aggression (Siever 2008). Notably, individuals exhibiting violent aggressive behavior have been found to show deficits in serotonergic transmission within the prefrontal cortex (Meyer et al. 2008). Further, the reduced serotonin levels in the prefrontal cortex-amygdala circuitry have been implicated in impulsive aggression (Passamonti et al. 2012).\u003c/p\u003e \u003cp\u003eAggression has been strongly linked to the inflammatory state in the body. Individuals with IED show elevated plasma inflammatory markers that correlate with aggression (Coccaro et al. 2014). Anger and interpersonal conflict can elevate cytokines such as TNF-α, especially in individuals displaying high hostility (Kiecolt-Glaser et al. 2005). Studies report a positive correlation between LPS-stimulated monocyte TNF-α expression and aggression in both males and females (Suarez et al. 2004). Similarly, T-cell-derived TNF-α levels are higher in individuals with greater hostility (Mommersteeg et al. 2008). Animal studies further support the immune system's involvement in aggression, as male mice lacking TNF receptors (TNF-R1 and TNF-R2) show reduced aggressive behavior in the resident-intruder test (Patel et al. 2010). Consistent with this, elevated TNF-α levels have been observed in highly aggressive individuals (Takahashi 2024). These data highlight the contributory role of inflammatory cytokines, particularly TNF-α, in aggressive behavior. It is important to note that peripheral TNF-α crosses the intact blood-brain barrier (BBB) through receptor-mediated transport mechanisms, which are upregulated under inflammatory conditions (Pan and Kastin 2007). In the brain, TNF-α activates the enzyme indoleamine 2,3 dioxygenase 1 (IDO1), which catabolizes tryptophan (serotonin precursor) into kynurenine, resulting in serotonin deficiency (Deore et al. 2024a; Sarangi 2024). These findings suggest that targeting TNF-α/IDO1 signaling can restore brain serotonin contents and suppress aggressive behavior.\u003c/p\u003e \u003cp\u003eOur recent findings suggest a critical role of the amygdala in the regulation of aggressive behavior (Chaudhari et al. 2025a). In restrained animals, we observed elevated levels of pro-inflammatory cytokines, including TNF-α, as well as a reduction in serotonin levels within the amygdala. These neurochemical changes indicate that the amygdala may be a key neural substrate mediating aggression under stress-related conditions. However, the role of peripheral immune activation in modulating central mechanisms of aggression has not been fully explored. In this context, Bacillus Calmette\u0026ndash;Gu\u0026eacute;rin (BCG), a well-established immune activator and model for chronic immune stimulation, offers a valuable tool to investigate how peripheral immune challenges influence brain function and behavior. While BCG has been extensively studied in the context of depression-like behavior, its effect on aggression remains poorly characterized. Therefore, examining BCG-induced changes in aggressive behavior could provide novel insights into the neuroimmune pathways, particularly within the amygdala, that mediate aggression in response to immune stressors.\u003c/p\u003e \u003cp\u003eIn the present study, we aimed to evaluate the effects of TNF-α and IDO1 inhibition in a mouse model of BCG-induced aggressive-like behavior. Inoculation of BCG in mice has been shown to elevate plasma TNF-α levels, increase brain IDO1 expression, and decrease serotonin levels (Deore et al. 2024a). BCG-treated mice received TNF-α inhibitor etanercept, either alone or in combination with the IDO1 inhibitor minocycline. Aggressive behavior was assessed using the social aggression test (SAT), which involved monitoring attacks on an unfamiliar intruder, and the rod biting test (RBT), where restrained mice were observed for rod-directed biting behavior. Following behavioral testing, the concentration of the plasma and amygdalar TNF-α levels was measured using ELISA, and serotonin content in the amygdala was quantified using high-performance liquid chromatography (HPLC). Our findings revealed that BCG induced aggressive behavior, elevated TNF-α, and reduced brain serotonin levels. These behavioral and biochemical changes were attenuated by etanercept and further enhanced by co-administration with minocycline.\u003c/p\u003e"},{"header":"2. Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Animals\u003c/h2\u003e \u003cp\u003eAdult male Swiss Albino mice weighing about 30 g were housed in polypropylene cages at constant room temperature (25\u0026thinsp;\u0026plusmn;\u0026thinsp;1\u0026deg;C), and relative humidity (50\u0026ndash;70%), and fed on a 12:12 h light-dark cycle. All behavioral tests were performed between 9:00 a.m. and 2:00 p.m. Chow food pellets (Nutrivet Life Sciences, Pune, India) and water were given \u003cem\u003ead libitum\u003c/em\u003e. All experimental protocols were sanctioned by the Institutional Animal Ethics Committee (IAEC) of SVKM's Institute of Pharmacy, Dhule, Maharashtra, India (SVKM-IOP/IAEC/2024/December/05).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. Drug preparations\u003c/h2\u003e \u003cp\u003eCommercial BCG preparation (Onco-BCG\u0026reg;, Serum Institute of India Pvt. Ltd., India) was used for the induction of aggressive-like phenotypes in mice. The vial contents were suspended in 4 mL saline to achieve a concentration of 10\u003csup\u003e9\u003c/sup\u003e CFU/mL (Vijaya Kumar et al. 2014). Commercially available injections of IDO1 inhibitor minocycline (Divaine\u0026reg;, Cipla Pharmaceuticals Ltd., India) and TNF-α inhibitor etanercept (Etacept\u0026reg;, Cipla Pharmaceuticals Ltd., India) were used. Lyophilized powder of etanercept was reconstituted with water for injection.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3. Experimental design\u003c/h2\u003e \u003cp\u003eThe mice were assigned randomly to various groups (n\u0026thinsp;=\u0026thinsp;6). BCG was inoculated (0.225 mL/mouse) via the intraperitoneal (i.p.) route on day 1 of the study, and housed individually. Then the animals received various treatments from days 15\u0026ndash;21 as stated below. Alongside, saline was administered to the control group.\u003c/p\u003e \u003cp\u003eGroup I : Control\u003c/p\u003e \u003cp\u003eGroup II : BCG (Disease control)\u003c/p\u003e \u003cp\u003eGroup III : BCG \u0026rarr; Etanercept (1.5 mg/kg, s.c.)\u003c/p\u003e \u003cp\u003eGroup IV : BCG \u0026rarr; Etanercept (3 mg/kg, s.c.)\u003c/p\u003e \u003cp\u003eGroup V : BCG \u0026rarr; Minocycline (25 mg/kg, i.p.)\u003c/p\u003e \u003cp\u003eGroup VI : BCG \u0026rarr; Minocycline (25 mg/kg, i.p.) + Etanercept (1.5 mg/kg, s.c.)\u003c/p\u003e \u003cp\u003eGroup VII : BCG \u0026rarr; Minocycline (25 mg/kg, i.p.) + Etanercept (3 mg/kg, s.c.)\u003c/p\u003e \u003cp\u003e On day 21, animals were subjected to behavioral studies followed by biochemical analysis of blood and brain samples. The experimental protocol is outlined in \u003cb\u003eFig.\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Behavioral Assessments\u003c/h2\u003e \u003cp\u003e \u003cem\u003eSocial Aggression Test (SAT)\u003c/em\u003e:\u003c/p\u003e \u003cp\u003eAttacking behavior towards an unfamiliar partner permits the measurement of reactive aggression. In this test, unfamiliar male mice were introduced into the home cages of the test mice. The unfamiliar partners were at least weighing 5 g less than the test animals (e.g., 25 g vs 30 g). The reactive aggressive behavior, i.e., the physical attack exhibited by the test mouse against an unfamiliar partner mouse, was monitored for 5 minutes. Once the experiment finished, the unfamiliar mouse was returned to its home cage (Kim et al. 2017). The interaction video was recorded from above using cameras, and the quantification of aggressive biting behavior was assessed.\u003c/p\u003e \u003cp\u003e \u003cem\u003eRod Biting Test (RBT)\u003c/em\u003e:\u003c/p\u003e \u003cp\u003eThe restraint-induced aggressive behavior in rodents has been validated in our laboratory (Chaudhari et al. 2025a). In this test, mouse was placed in the in-house fabricated restrainer for 5 minutes. Subsequently, a removable metal rod (4 cm in length and 5 mm in diameter) was inserted at the end of the restrainer, positioned near the animal's nose. The rod was consisted of two parallel metals connected to an electrical circuit and a counter. When animal bites the rod, the electric circuit completed and number of bites were recorded. The number of rod bites by the restrained mouse was counted for 3 minutes and used as an index of IED (Kuchiiwa and Kuchiiwa 2014).\u003c/p\u003e \u003cp\u003e \u003cem\u003eOpen field test (OFT)\u003c/em\u003e \u003c/p\u003e \u003cp\u003eTo test the effect of various treatments on locomotor activity, the OFT was conducted based on protocols from earlier research (Deore et al. 2024b; Awathale et al. 2025; Shirasath et al. 2025). The OFT apparatus (50 \u0026times; 50 \u0026times; 20 cm) was equipped with invisible vertical and parallel infrared (IR) beams connected to an actimeter system. Each mouse was individually placed at the center of the arena and observed for 5 minutes. Locomotor activity was automatically recorded by counting the number of IR beam interruptions, expressed as actimeter counts. To eliminate residual odors, the arena was cleaned with 70% alcohol after each trial.\u003c/p\u003e \u003cp\u003e \u003cb\u003eBlood sample collection\u003c/b\u003e \u003c/p\u003e \u003cp\u003eImmediately after RBT, all the mice from control, diseased and treatment groups (Groups I to VII) were deeply anesthetized by overdose of thiopentone sodium (75 mg/kg; i.p.). The blood samples were collected by retro-orbital puncture in EDTA tubes. Blood samples were centrifuged at 10000xg for 15 min at 4\u0026deg;C. The plasma supernatant was collected, and the levels of TNF-α were determined using ELISA kits.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5. Preparation tissue homogenate\u003c/h2\u003e \u003cp\u003eAfter completion of the behavioral assessment and blood withdrawal, mice from various experimental groups [(saline, BCG, BCG\u0026thinsp;+\u0026thinsp;etanercept (3 mg/kg) and BCG\u0026thinsp;+\u0026thinsp;etanercept (3 mg/kg) + minocycline (25 mg/kg)] were sacrificed using thiopentone sodium (75 mg/kg, ip), the brains were isolated and kept at -80\u0026deg;C. Amygdala from both hemispheres were separated using a biopsy punch (2 mm diameter). Tissues were homogenized in 500 \u0026micro;l 0.1 N perchloric acid and centrifuged at 10000\u0026times;g for 5 min at 4\u0026deg;C. Tissue samples were taken from coronal brain sections spanning bregma coordinates\u0026thinsp;\u0026minus;\u0026thinsp;2.12 mm to -2.80 mm, based on the rat brain atlas by Paxinos and Watson (1998), to maintain anatomical consistency among all subjects. The collected tissue was then homogenized in ice-cold PBS at pH 7.5. The resulting homogenate was transferred to Eppendorf tubes and centrifuged at 10000xg at 0\u0026deg;C for 10 minutes. The supernatant was then collected and stored at -20\u0026deg;C for further analysis. (Deore et al. 2024b; Pardeshi et al. 2025; Awathale et al. 2025; Chaudhari et al. 2025a). Half of the supernatant was utilized for ELISA, and the remaining was used for HPLC analysis.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.6. Determination of concentration of TNF-α in the plasma and the amygdala\u003c/h2\u003e \u003cp\u003eFor the determination of plasma TNF-α, 100 \u0026micro;L of the plasma samples and standards were added to a 96-well plate in triplicate. The total protein content in the supernatant of the amygdala was measured using the bicinchoninic acid (BCA) assay. Protein concentrations were then adjusted to 1 \u0026micro;g/\u0026micro;L using PBS. Each tissue sample (100 \u0026micro;L, equivalent to 100 \u0026micro;g of protein) was loaded in triplicate into a 96-well plate along with the standards. The concentrations of TNF-α in the plasma and amygdala were quantified following the manufacturer\u0026rsquo;s instructions mentioned in the ELISA kits (Cat No. ELK1396, ELK Biotechnology Co. Ltd., USA) (Pardeshi et al. 2025; Chaudhari et al. 2025b).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e2.7. Measurement of serotonin in the amygdala by using high-performance liquid chromatography (HPLC)\u003c/h2\u003e \u003cp\u003eThe method of HPLC was adopted from our previous studies (Deore et al. 2024a; Pardeshi et al. 2025; Chaudhari et al. 2025a). The supernatant was removed and filtered through a nylon filter (22 \u0026micro;m), again centrifuged at 12,000 rpm for 5 min at 4\u0026deg;C (O\u0026rsquo;Connor et al. 2009). The supernatant was removed and diluted with 0.02 N perchloric acid at a 1:100 ratio (v:v). These samples were injected into the HPLC system for the determination of serotonin (O\u0026rsquo;Connor et al. 2009; Awathale et al. 2020). Serotonin levels in the tissue homogenate were analyzed by HPLC using a photodiode array detector, and the isocratic reverse phase-HPLC was performed on Sunfire C18 column (250 mm \u0026times; 4.6 mm, 5 \u0026micro;m). The mobile phases consisted of potassium dihydrogen phosphate (KH\u003csub\u003e2\u003c/sub\u003ePO\u003csub\u003e4\u003c/sub\u003e)/acetonitrile (90:10 v/v). The flow rate was maintained at 1.0 mL/min, and the run time was 8 min. Serotonin content in the amygdala was analyzed at +\u0026thinsp;320 mV. The injection volume (20 \u0026micro;l) of tissue homogenate was injected into the HPLC system. The retention time (RT) of each sample peak was recorded and compared with the RT of the external standard of serotonin (Sigma, USA; Cat No. H9523) prepared in 0.02 N perchloric acid. The area under the curve (AUC) of each chromatogram was quantified using Empower 3 software (Waters Instrument) and expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard error of the mean (SEM) (Awathale et al. 2020).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e2.8. Statistical analysis\u003c/h2\u003e \u003cp\u003eThe data are represented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SEM. The statistical analysis of the data was performed by one-way ANOVA, followed by post-hoc Bonferroni\u0026rsquo;s multiple comparisons tests using GraphPad Prism software. The normal distribution of data was calculated by using the online calculator present at the Statistics Kingdom website (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.statskingdom.com/shapiro-wilk-test-calculator.html\u003c/span\u003e\u003cspan address=\"https://www.statskingdom.com/shapiro-wilk-test-calculator.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e); all the data were found to be normally distributed. Applications of Grubbs\u0026rsquo; test revealed no outliers across the data. The data was considered significant if p\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e3.1. Effect of etanercept on SAT, and its modulation by minocycline in BCG-inoculated mice\u003c/h2\u003e \u003cp\u003eThe effect of BCG inoculation on the aggressive behavior of test mice with unfamiliar mice was screened using SAT. Further, the effects of etanercept, alone and jointly with minocycline, were screened. Application of one-way ANOVA showed a significant change in the number of attacks within different groups of mice [F (6, 35)\u0026thinsp;=\u0026thinsp;54.04, p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, Fig.\u0026nbsp;2A]. Post-hoc Bonferroni\u0026rsquo;s multiple comparisons test revealed a significant elevation in the number of attacks in BCG- inoculated mice as compared to the control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). This suggests the induction of aggressive behavior by BCG. Etanercept at the dose of 1.5 mg/kg produced a non-significant decrease in the number of attacks (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05) and at the 3 mg/kg dose decreased the number of attacks as compared to the disease control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001), suggesting it reduces aggressive behavior.\u003c/p\u003e \u003cp\u003eMinocycline at a 25 mg/kg dose produced a non-significant reduction in the number of attacks compared to disease control (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Interestingly, its combination with a subeffective dose of etanercept (1.5 mg/kg) resulted in a significant decrease in the number of attacks as compared to disease control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and etanercept alone at 1.5 mg/kg (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). Likewise, minocycline potentiated the effect of etanercept (3 mg/kg) and significantly decreased the number of attacks as compared to the BCG only (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and etanercept alone (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Fig.\u0026nbsp;2A).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e3.2. Effect of etanercept on RBT, and its modulation by minocycline in BCG-inoculated mice\u003c/h2\u003e \u003cp\u003eApplication of one-way ANOVA showed a significant change in the number of bites within different groups of mice [F (6, 35)\u0026thinsp;=\u0026thinsp;148.9, p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, Fig.\u0026nbsp;2B]. Post-hoc Bonferroni\u0026rsquo;s multiple comparisons test revealed that the number of Bites was increased in BCG-inoculated mice as compared to the control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). Etanercept at the dose of 1.5 mg/kg produced a non-significant decrease in the number of bites (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05) and at the 3 mg/kg dose decreased the number of Bites as compared to the disease control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001).\u003c/p\u003e \u003cp\u003eMinocycline at 25 mg/kg dose produced a non-significant reduction in the number of Bites compared to disease control (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Interestingly, its combination with a subeffective dose of etanercept (1.5 mg/kg) resulted in a significant decrease in the number of Bites as compared to disease control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and per se treatment of etanercept (1.5 mg/kg) (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). Likewise, minocycline significantly potentiated the effect of etanercept (3 mg/kg) and decreases the number of Bites as compared disease control (p\u0026thinsp;\u0026lt;\u0026thinsp;0.0001) and etanercept alone (3 mg/kg) (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01) (Fig.\u0026nbsp;2B). Although per se treatment with minocycline (25 mg/kg) or etanercept (1.5 mg/kg) failed to show a noticeable effect on Aggressive Biting behavior, a non-significantly decreased number of bites were observed (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05) as compared to disease control. This suggests that the combination of minocycline and etanercept reduces aggressive behavior through IDO1 and TNF-α inhibition. These data reflect that there is functional synergism between etanercept and minocycline with respect to aggressive behavior.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003e3.3. Effect of etanercept on locomotor activity, and its modulation by minocycline in BCG-inoculated mice\u003c/h2\u003e \u003cp\u003eThe effect of etanercept and minocycline on locomotor activity using OFT in different groups of mice. The data were analyzed by one-way ANOVA revealed no significant changes in locomotor count among all experimental groups [F (6, 35)\u0026thinsp;=\u0026thinsp;99.44, p\u0026thinsp;=\u0026thinsp;0.4443, Fig.\u0026nbsp;2C]. The post-hoc analysis using Bonferroni\u0026rsquo;s multiple comparisons test demonstrated no significant alterations in locomotor activity among all groups of animals (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). These results indicate that neither etanercept nor its combination with minocycline affects locomotor activity, thereby ruling out any cofounding influence of locomotion on the aggressive behavior with unfamiliar mice and with rod activity.\u003c/p\u003e \u003cp\u003e\u003cstrong\u003e3.4. Effect of etanercept on TNF-\u0026alpha; concentration in the plasma and amygdala of mice with aggressive-like behavior, and their modulation by minocycline\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe concentrations of pro-inflammatory marker, TNF-\u0026alpha;, in BCG-treated mice with etanercept (1.5 and 3 mg/kg), alone and in combination with minocycline (25 mg/kg), were determined in plasma using ELISA. Application of one-way ANOVA showed a significant variation in the plasma concentration of TNF-\u0026alpha; among the different groups of mice [F (6, 35) = 97.14, p \u0026lt; 0.0001, Fig. 3A] and in amygdala [F (6, 35) = 14.88, p \u0026lt; 0.0001, Fig. 3B]. Post-hoc Bonferroni\u0026apos;s multiple comparisons test revealed a significant increase in the concentrations of plasma and amygdala TNF-\u0026alpha; in the BCG-treated mice as compared to the control (both p \u0026lt; 0.001), indicating that BCG increases pro-inflammatory cytokine concentration in periphery as well as in brain (amygdala). Subeffective dose of etanercept (1.5 mg/kg) shows a non-significant decrease in the level of TNF-\u0026alpha; in plasma (Fig. 3A) and amygdala (Fig. 3B) as compared to disease control mice (p \u0026gt; 0.05). Moreover, effective dose of etanercept (3 mg/kg) decreases the level of TNF-\u0026alpha; in plasma and amygdala as compared to disease control mice (both p \u0026lt; 0.05).\u003c/p\u003e\n\u003cp\u003eAdministration of minocycline at a 25 mg/kg dose showed a non-significant change in the level of TNF-\u0026alpha; (p \u0026gt; 0.05). Co-administration of etanercept (1.5 mg/kg) with minocycline (25 mg/kg) further reduced the TNF-\u0026alpha; content in plasma (p \u0026lt; 0.05) and amygdala (p \u0026lt; 0.01). However, minocycline potentiated the effect of etanercept (3 mg/kg) (p \u0026lt; 0.001) and significantly decreased plasma and amygdala TNF-\u0026alpha; level as compared to etanercept alone both (p \u0026lt; 0.001) (Fig. 3A and B). This suggests that minocycline potentiated the effect of etanercept and significantly reduced plasma and amygdala TNF-\u0026alpha; level, which was accompanied by alleviating the aggression-like phenotype in mice.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.5. Effect of BCG, etanercept and their combination with minocycline on levels of serotonin in the mice brain\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe effect of etanercept and combination with minocycline on the brain serotonin levels was determined using HPLC systems. Application of one-way ANOVA showed significant alteration in the levels of serotonin [chromatograms in Fig. 4A\u0026ndash;E; AUC, F (3, 20) = 1471, p \u0026lt; 0.0001, Fig. 4E]. Post-hoc Bonferroni\u0026rsquo;s multiple comparisons test revealed that the AUC of the 5-HT were significantly decreased in the BCG-injected mice as compared to control (p \u0026lt; 0.001, Fig. 4E). \u003c/p\u003e\n\u003cp\u003eHowever, etanercept at the dose of 3 mg/kg significantly increased the AUC of serotonin as compared to the disease control mice (p \u0026lt; 0.001, Fig. 4E). Furthermore, etanercept (3 mg/kg) in combination with minocycline (25 mg/kg) significantly increased the AUC of the serotonin as compared to the disease control mice and etanercept alone (p \u0026lt; 0.0001, Fig. 4E). These data indicate that BCG lowers the levels of serotonin which may be contributed to the induction of Aggressive behavior in mice. Moreover, the injection of etanercept alone and in combination with minocycline improves the levels of 5-HT, suggesting its alleviating aggressive behavior that might be associated with the modulation of the TNF-\u0026alpha; receptor and IDO1 enzyme.\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eAggression can be induced by a number of risk factors, including biological and psychological, for example, genetics and mental illnesses, and socioeconomic (Fritz et al. 2023). The current study investigated the mechanisms through which BCG-induced systemic inflammation and influences aggression-like behavior in mice and examined the therapeutic potential of etanercept, a TNF-α inhibitor, and minocycline, an IDO1 inhibitor, alone and in combination. One of the key outcomes of this research is the development of BCG-induced aggression as a reproducible and stable model to investigate the effects of chronic neuroinflammation on behavior. BCG immunization robustly enhanced aggressive-like behaviors in the SIT and RBT. These behavioral modifications were accompanied by biochemical changes in proinflammatory cytokines and serotonin content, highlighting the neuroimmune connection in aggression.\u003c/p\u003e \u003cp\u003ePathological aggression levels in intermittent IED or psychosis seem to be associated with increased proinflammatory cytokines (Bhatt et al. 2008; Das et al. 2016). Our results support the perspective that immune system activation is important in the modulation of behavioral states. The BCG vaccine, although conventionally employed as a protective measure against tuberculosis, is recognized to cause systemic immune activation. In our research, it robustly increased plasma TNF-α levels, an important cytokine that affects CNS function and is frequently involved in mood and behavioral disorders.\u003c/p\u003e \u003cp\u003eIn dendritic cells TNF-α activate the JAK/STAT pathway \u0026amp; these stimuli result in IDO1 activation (Manches et al. 2012). Blood-brain barrier endothelial cells utilize IDO1 for the degradation of tryptophan into kynurenine for the maintenance of their function (Adam et al. 2005). L-tryptophan is not only a building block of proteins but also a precursor to serotonin synthesis (Comai et al. 2020). However, the major metabolic pathway of L-tryptophan is the catabolic pathway catalyzed by IDO1 enzyme that converts L-tryptophan to kynurenine and its metabolites, especially in inflammatory states (Badawy 2017; Pallotta et al. 2022). Under conditions of inflammation, over 95% of free L-tryptophan can be catabolized via the kynurenine pathway.\u003c/p\u003e \u003cp\u003eIn the present investigation, mice subjected to restraint stress showed elevated TNF-α concentration in the amygdala, associated with defensive rage (Pesce et al. 2011). The role of the central amygdala in the pathology of aggression and violence has been well documented (Haller 2018). Maternal separation-induced aggression triggers a higher activation of the amygdala (Ohta et al. 2023). Therefore, in the present investigation, the involvement of TNF-α of the amygdala in the regulation of aggressive phenotype was tested. While restraint stress equipped with a biting rod elevates TNF-α in the amygdala, etanercept alone and in combination with minocycline significantly reduces its level. These results demonstrated that antagonism of the TNF-α-IDO1 interaction in the amygdala might have a regulatory effect on aggressive biting behavior in BCG-inoculated mice.\u003c/p\u003e \u003cp\u003eWhereas IDO1 activation in neuroinflammation induces serotonin production deficiency that can in-turn trigger psychiatric diseases (Jeon and Kim 2017). Dysregulation of the serotonin system has been implicated in the hyperexpression of aggression (Miczek et al. 2007). In line with this, our HPLC results indicated a marked reduction in brain serotonin levels in BCG-inoculated mice as compared to controls, which supports the mechanistic pathway of systemic inflammation leading to modified serotonergic signaling.\u003c/p\u003e \u003cp\u003eThe behavioral effects showed that etanercept, especially at a higher dose of 5 mg/kg, highly decreased aggressive behaviors in both tests. This indicates that inhibition of TNF-α signaling alone is enough to weaken some of the effects of BCG for inducing aggression. Interestingly, although minocycline alone had a non-significant effect, a combination of it with a sub-effective and effective dose of etanercept was highly effective in reducing aggression. This suggests that there is a synergistic interaction between TNF-α and IDO1 pathways in controlling aggression. Combined treatment perhaps has dual inhibition preventing the release of pro-inflammatory cytokines and inhibiting tryptophan catabolism, thus maintaining serotonin levels and mood and behavioral stabilization.\u003c/p\u003e \u003cp\u003eThis observation fits with the wider context of neuroimmune communication, in which cytokines and immune-activated enzymes communicate with neurotransmitter systems to have an effect on behavior. Stress-induced increased peripheral inflammation modulates BBB permeability, facilitating infiltration of freely circulating inflammatory factors into mood‐associated brain regions' parenchyma, leading to damage and neural circuit modification (Miller and Raison 2016; Menard et al. 2017; Beurel et al. 2020). Inflammatory stimuli were found to affect brain areas associated with emotional processing, such as the amygdala (Anisman et al. 2008; Mehta et al. 2022). The amygdala is the core of a neural system that deals with affective stimulus, particularly negatively valenced stimulus and aggression (Singh and Gobrogge 2024; Chaudhari et al. 2025b). Violent criminals have lower levels of serotonin than do nonviolent criminals, and criminals convicted of impulsive violent crimes have lower serotonin levels than criminals convicted of premeditated crimes (Virkkunen et al. 1987). So, the decreased serotonin in our BCG-injected mice probably caused this imbalance, impairing behavioral inhibition and increasing reactivity to provocation.\u003c/p\u003e \u003cp\u003eIn addition, our research provides a translational perspective through the employment of clinical agents, pharmacologically available etanercept and minocycline. Etanercept, a biologic inhibitor of TNF have since been clinically effective in lowering inflammation related to a number of autoimmune disorders, including rheumatoid arthritis, psoriasis and Crohn's disease (Croft et al. 2024). It exhibits a significant effect on the inhibition of inflammation (Li et al. 2022). Minocycline is a tetracycline antibiotic with extensive anti-inflammatory effects and excellent central nervous system penetration. Thus, it has anti-inflammatory and neuroprotective effects and has been investigated for mood disorders as well as in other psychiatric diseases like bipolar disease and schizophrenia (Nettis 2021). The efficacy of these agents in suppressing aggression in our model suggests their potential for repurposing towards the treatment of neuroinflammation-related behavioral disorders.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eThe cytokine model of depression suggests that raised levels of proinflammatory cytokines including IL-6 and TNF-α, may be involved in the etiology of depressive symptoms and influence mood regulation and play a role in the episodic nature of the disorder. Neuroinflammation may interfere with neurotransmitter systems involved in depression, such as serotonin, dopamine, and glutamate (Levin 2024). Moreover, high states of anger (acute episodes of anger) also induce proinflammatory cytokine release (Kiecolt-Glaser et al. 2005). A modulating function of cytokines in mammalian aggressive behavior is implicated by direct experimental manipulation in lower mammals (Zalcman and Siegel 2006; Bhatt et al. 2008; Coccaro et al. 2015), by inflammatory cytokines' effect on anger and aggression in patients undergoing cytokine immunotherapy (McHutchison et al. 1998; Kraus et al. 2003). It is also noteworthy that the above data support the cytokine theory of affective disorders, which posits that elevated levels of proinflammatory cytokines can influence mood, behavior, and emotional regulation, thereby contributing to increased anger and aggression.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKartik T. Nakhate acknowledges the Indian Council of Medical Research (ICMR), Government of India, New Delhi (Ad-hoc Project ID: 2021\u0026ndash;11133) and SEED Grant SVKM\u0026rsquo;s Institute of Pharmacy, Dhule, MH, India for research funding (Grant No. SVKM/IOP/ 2023\u0026ndash;24/1303H).\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCRediT authorship contribution statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePooja Patil and Dhiraj Vispute\u003c/strong\u003e: Conceptualization, Writing-original draft, Methodology, Formal analysis, Investigation, Writing-review \u0026amp; editing, Visualization. \u003cstrong\u003eSameer N. Goyal:\u003c/strong\u003e Writing-review \u0026amp; editing, Validation, Resources, Formal analysis, Funding acquisition. \u003cstrong\u003eSanjay Awathale and Kartik T. Nakhate:\u003c/strong\u003e Conceptualization, Methodology, Supervision, Writing-review \u0026amp; editing, Visualization, Validation, Investigation, Formal analysis, Project administration. All authors reviewed the results and approved the final manuscript version. \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDeclaration of competing interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding Declaration \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was supported by the Indian Council of Medical Research (ICMR), Government of India, New Delhi (Ad-hoc Project ID: 2021\u0026ndash;11133) and SEED Grant SVKM\u0026rsquo;s Institute of Pharmacy, Dhule, MH, India for research funding (Grant No. SVKM/IOP/ 2023\u0026ndash;24/1303H).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData will be made available on request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAdam R, R\u0026uuml;ssing D, Adams O, et al (2005) Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2,3-dioxygenase in antimicrobial defence and immunoregulation. Thromb Haemost 94:341\u0026ndash;346. https://doi.org/10.1160/TH05-01-0053\u003c/li\u003e\n\u003cli\u003eAnisman H, Merali Z, Hayley S (2008) Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Progress in Neurobiology 85:1\u0026ndash;74. https://doi.org/10.1016/j.pneurobio.2008.01.004\u003c/li\u003e\n\u003cli\u003eAwathale SN, Dudhbhate BB, Rahangdale RR, et al (2020) Denial of food to the hungry rat: a novel paradigm for induction and evaluation of anger-like emotion. Journal of Neuroscience Methods 341:108791\u003c/li\u003e\n\u003cli\u003eAwathale SN, Shirasath KR, More BR, et al (2025) Naringenin prevents ethanol-induced reward behavior in adolescent rats through inhibition of TRPM3-dependent inflammation in the pVTA. J Nutr Biochem 110078. https://doi.org/10.1016/j.jnutbio.2025.110078\u003c/li\u003e\n\u003cli\u003eBadawy AA-B (2017) Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res 10:1178646917691938. https://doi.org/10.1177/1178646917691938\u003c/li\u003e\n\u003cli\u003eBeurel E, Toups M, Nemeroff CB (2020) The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 107:234\u0026ndash;256. https://doi.org/10.1016/j.neuron.2020.06.002\u003c/li\u003e\n\u003cli\u003eBhatt S, Bhatt R, Zalcman SS, Siegel A (2008) Role of IL-1 beta and 5-HT2 receptors in midbrain periaqueductal gray (PAG) in potentiating defensive rage behavior in cat. Brain Behav Immun 22:224\u0026ndash;233. https://doi.org/10.1016/j.bbi.2007.07.011\u003c/li\u003e\n\u003cli\u003eBlair RJR (2016) The Neurobiology of Impulsive Aggression. J Child Adolesc Psychopharmacol 26:4\u0026ndash;9. https://doi.org/10.1089/cap.2015.0088\u003c/li\u003e\n\u003cli\u003eChaudhari AK, Shirasath KR, Goyal SN, et al (2025a) A novel biting rod model for assessing aggressive behavior in restraint-stressed rats: Role of 5-HT3 receptor and NF-\u0026kappa;B-kynurenine pathways. Physiol Behav 115091. https://doi.org/10.1016/j.physbeh.2025.115091\u003c/li\u003e\n\u003cli\u003eCoccaro EF, Lee R, Coussons-Read M (2014) Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. JAMA Psychiatry 71:158\u0026ndash;165. https://doi.org/10.1001/jamapsychiatry.2013.3297\u003c/li\u003e\n\u003cli\u003eCoccaro EF, Lee R, Coussons-Read M (2015) Cerebrospinal Fluid Inflammatory Cytokines and Aggression in Personality Disordered Subjects. Int J Neuropsychopharmacol 18:pyv001. https://doi.org/10.1093/ijnp/pyv001\u003c/li\u003e\n\u003cli\u003eComai S, Bertazzo A, Brughera M, Crotti S (2020) Chapter Five - Tryptophan in health and disease. In: Makowski GS (ed) Advances in Clinical Chemistry. Elsevier, pp 165\u0026ndash;218\u003c/li\u003e\n\u003cli\u003eCroft M, Salek-Ardakani S, Ware CF (2024) Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov 23:939\u0026ndash;961. https://doi.org/10.1038/s41573-024-01053-9\u003c/li\u003e\n\u003cli\u003eDas S, Deuri SK, Sarmah A, et al (2016) Aggression as an independent entity even in psychosis- the role of inflammatory cytokines. Journal of Neuroimmunology 292:45\u0026ndash;51. https://doi.org/10.1016/j.jneuroim.2016.01.012\u003c/li\u003e\n\u003cli\u003eDeore R, Ansari R, Awathale SN, et al (2024a) Lycopene alleviates BCG-induced depressive phenotypes in mice by disrupting 5-HT3 receptor - IDO1 interplay in the brain. Eur J Pharmacol 977:176707. https://doi.org/10.1016/j.ejphar.2024.176707\u003c/li\u003e\n\u003cli\u003eDuke AA, B\u0026egrave;gue L, Bell R, Eisenlohr-Moul T (2013) Revisiting the serotonin-aggression relation in humans: a meta-analysis. Psychol Bull 139:1148\u0026ndash;1172. https://doi.org/10.1037/a0031544\u003c/li\u003e\n\u003cli\u003eFritz M, Soravia S-M, Dudeck M, et al (2023) Neurobiology of Aggression\u0026mdash;Review of Recent Findings and Relationship with Alcohol and Trauma. Biology (Basel) 12:469. https://doi.org/10.3390/biology12030469\u003c/li\u003e\n\u003cli\u003eHaller J (2018) The role of central and medial amygdala in normal and abnormal aggression: A review of classical approaches. Neuroscience \u0026amp; Biobehavioral Reviews 85:34\u0026ndash;43. https://doi.org/10.1016/j.neubiorev.2017.09.017\u003c/li\u003e\n\u003cli\u003eHalvachizadeh S, Mariani D, Pfeifer R (2025) Impact of trauma on society. Eur J Trauma Emerg Surg 51:155. https://doi.org/10.1007/s00068-025-02824-8\u003c/li\u003e\n\u003cli\u003eJeon SW, Kim Y-K (2017) Inflammation-induced depression: Its pathophysiology and therapeutic implications. J Neuroimmunol 313:92\u0026ndash;98. https://doi.org/10.1016/j.jneuroim.2017.10.016\u003c/li\u003e\n\u003cli\u003eKiecolt-Glaser JK, Loving TJ, Stowell JR, et al (2005) Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry 62:1377\u0026ndash;1384. https://doi.org/10.1001/archpsyc.62.12.1377\u003c/li\u003e\n\u003cli\u003eKim H-D, Call T, Carotenuto S, et al (2017) Testing Depression in Mice: a Chronic Social Defeat Stress Model. Bio Protoc 7:e2203. https://doi.org/10.21769/BioProtoc.2203\u003c/li\u003e\n\u003cli\u003eKraus MR, Sch\u0026auml;fer A, Faller H, et al (2003) Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64:708\u0026ndash;714. https://doi.org/10.4088/jcp.v64n0614\u003c/li\u003e\n\u003cli\u003eKuchiiwa S, Kuchiiwa T (2014) A novel semi-automated apparatus for measurement of aggressive biting behavior in mice. J Neurosci Methods 228:27\u0026ndash;34. https://doi.org/10.1016/j.jneumeth.2014.02.017\u003c/li\u003e\n\u003cli\u003eLevin M (2024) The Role of Neuroinflammation in Psychiatric Disorders. Neuroscience and Psychiatry: Open Access 7:265\u0026ndash;267. https://doi.org/10.47532/npoa.2024.7(5).265-267\u003c/li\u003e\n\u003cli\u003eLi Y, Fan H, Ni M, et al (2022) Etanercept Reduces Neuron Injury and Neuroinflammation via Inactivating c-Jun N-terminal Kinase and Nuclear Factor-\u0026kappa;B Pathways in Alzheimer\u0026rsquo;s Disease: An In Vitro and In Vivo Investigation. Neuroscience 484:140\u0026ndash;150. https://doi.org/10.1016/j.neuroscience.2021.11.001\u003c/li\u003e\n\u003cli\u003eLischinsky JE, Lin D (2020) Neural mechanisms of aggression across species. Nat Neurosci 23:1317\u0026ndash;1328. https://doi.org/10.1038/s41593-020-00715-2\u003c/li\u003e\n\u003cli\u003eLiu F, Yin X (2024) Psychological and pharmacological treatments of intermittent explosive disorder: a meta-analysis protocol. BMJ Open 14:e083896. https://doi.org/10.1136/bmjopen-2024-083896\u003c/li\u003e\n\u003cli\u003eManches O, Fernandez MV, Plumas J, et al (2012) Activation of the noncanonical NF-\u0026kappa;B pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci U S A 109:14122\u0026ndash;14127. https://doi.org/10.1073/pnas.1204032109\u003c/li\u003e\n\u003cli\u003eManuck SB, Flory JD, Ferrell RE, et al (1999) Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. Biol Psychiatry 45:603\u0026ndash;614. https://doi.org/10.1016/s0006-3223(98)00375-8\u003c/li\u003e\n\u003cli\u003eMcHutchison JG, Gordon SC, Schiff ER, et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485\u0026ndash;1492. https://doi.org/10.1056/NEJM199811193392101\u003c/li\u003e\n\u003cli\u003eMehta ND, Stevens JS, Li Z, et al (2022) Inflammation, Amygdala-Ventromedial Prefrontal Functional Connectivity and Symptoms of Anxiety and PTSD in African American Women Recruited from an Inner-City Hospital: Preliminary Results. Brain Behav Immun 105:122\u0026ndash;130. https://doi.org/10.1016/j.bbi.2022.06.013\u003c/li\u003e\n\u003cli\u003eMenard C, Pfau ML, Hodes GE, et al (2017) Social stress induces neurovascular pathology promoting depression. Nat Neurosci 20:1752\u0026ndash;1760. https://doi.org/10.1038/s41593-017-0010-3\u003c/li\u003e\n\u003cli\u003eMeyer JH, Wilson AA, Rusjan P, et al (2008) Serotonin2A receptor binding potential in people with aggressive and violent behaviour. J Psychiatry Neurosci 33:499\u0026ndash;508\u003c/li\u003e\n\u003cli\u003eMiczek KA, de Almeida RMM, Kravitz EA, et al (2007) Neurobiology of escalated aggression and violence. J Neurosci 27:11803\u0026ndash;11806. https://doi.org/10.1523/JNEUROSCI.3500-07.2007\u003c/li\u003e\n\u003cli\u003eMiller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22\u0026ndash;34. https://doi.org/10.1038/nri.2015.5\u003c/li\u003e\n\u003cli\u003eMommersteeg PMC, Vermetten E, Kavelaars A, et al (2008) Hostility is related to clusters of T-cell cytokines and chemokines in healthy men. Psychoneuroendocrinology 33:1041\u0026ndash;1050. https://doi.org/10.1016/j.psyneuen.2008.05.007\u003c/li\u003e\n\u003cli\u003eNettis MA (2021) Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders. Brain Behav Immun Health 17:100335. https://doi.org/10.1016/j.bbih.2021.100335\u003c/li\u003e\n\u003cli\u003eO\u0026rsquo;Connor JC, Andr\u0026eacute; C, Wang Y, et al (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29:4200\u0026ndash;4209. https://doi.org/10.1523/JNEUROSCI.5032-08.2009\u003c/li\u003e\n\u003cli\u003eOhta K, Araki C, Ujihara H, et al (2023) Maternal separation early in life induces excessive activity of the central amygdala related to abnormal aggression. Journal of Neurochemistry 167:778\u0026ndash;794. https://doi.org/10.1111/jnc.16020\u003c/li\u003e\n\u003cli\u003ePallotta MT, Rossini S, Suvieri C, et al (2022) Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme. FEBS J 289:6099\u0026ndash;6118. https://doi.org/10.1111/febs.16086\u003c/li\u003e\n\u003cli\u003ePan W, Kastin AJ (2007) Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 83:363\u0026ndash;374. https://doi.org/10.1016/j.pneurobio.2007.07.008\u003c/li\u003e\n\u003cli\u003ePardeshi GN, Ali N, Shirasath KR, et al (2025) Inhibition of TRPM3 channels in the medial prefrontal cortex mitigates OCD symptoms following traumatic brain injury. Inflammopharmacol. https://doi.org/10.1007/s10787-025-01763-5\u003c/li\u003e\n\u003cli\u003ePassamonti L, Crockett MJ, Apergis-Schoute AM, et al (2012) Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. Biol Psychiatry 71:36\u0026ndash;43. https://doi.org/10.1016/j.biopsych.2011.07.033\u003c/li\u003e\n\u003cli\u003ePatel A, Siegel A, Zalcman SS (2010) Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav Immun 24:1276\u0026ndash;1280. https://doi.org/10.1016/j.bbi.2010.05.005\u003c/li\u003e\n\u003cli\u003ePesce M, Speranza L, Franceschelli S, et al (2011) Biological role of interleukin-1beta in defensive-aggressive behaviour. J Biol Regul Homeost Agents 25:323\u0026ndash;329\u003c/li\u003e\n\u003cli\u003eRen J, Isakova A, Friedmann D, et al (2019) Single-cell transcriptomes and whole-brain projections of serotonin neurons in the mouse dorsal and median raphe nuclei. eLife 8:e49424. https://doi.org/10.7554/eLife.49424\u003c/li\u003e\n\u003cli\u003eRosell DR, Siever LJ (2015) The neurobiology of aggression and violence. CNS Spectr 20:254\u0026ndash;279. https://doi.org/10.1017/S109285291500019X\u003c/li\u003e\n\u003cli\u003eSarangi P (2024) Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer. Cancer Pathogenesis and Therapy 2:246\u0026ndash;255. https://doi.org/10.1016/j.cpt.2023.11.001\u003c/li\u003e\n\u003cli\u003eShirasath KR, Chaudhari AK, Nakhate KT, et al (2025) Plumbagin Alleviates Mild Traumatic Brain Injury-Induced Obsessive-Compulsive Disorder in Mice by Inhibiting nNOS and Augmenting Cortico-Striatal Serotonin Levels. Phytother Res. https://doi.org/10.1002/ptr.70105\u003c/li\u003e\n\u003cli\u003eSiever LJ (2008) Neurobiology of Aggression and Violence. Am J Psychiatry 165:429\u0026ndash;442. https://doi.org/10.1176/appi.ajp.2008.07111774\u003c/li\u003e\n\u003cli\u003eSingh R, Gobrogge K (2024) Aggression Unleashed: Neural Circuits from Scent to Brain. Brain Sci 14:794. https://doi.org/10.3390/brainsci14080794\u003c/li\u003e\n\u003cli\u003eSuarez EC, Lewis JG, Krishnan RR, Young KH (2004) Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 29:1119\u0026ndash;1128. https://doi.org/10.1016/j.psyneuen.2004.01.002\u003c/li\u003e\n\u003cli\u003eTakahashi A (2024) Associations of the immune system in aggression traits and the role of microglia as mediators. Neuropharmacology 256:110021. https://doi.org/10.1016/j.neuropharm.2024.110021\u003c/li\u003e\n\u003cli\u003eVijaya Kumar K, Rudra A, Sreedhara MV, et al (2014) Bacillus Calmette-Gu\u0026eacute;rin vaccine induces a selective serotonin reuptake inhibitor (SSRI)-resistant depression like phenotype in mice. Brain Behav Immun 42:204\u0026ndash;211. https://doi.org/10.1016/j.bbi.2014.06.205\u003c/li\u003e\n\u003cli\u003eVirkkunen M, Nuutila A, Goodwin FK, Linnoila M (1987) Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry 44:241\u0026ndash;247. https://doi.org/10.1001/archpsyc.1987.01800150053007\u003c/li\u003e\n\u003cli\u003eZalcman SS, Siegel A (2006) The neurobiology of aggression and rage: role of cytokines. Brain Behav Immun 20:507\u0026ndash;514. https://doi.org/10.1016/j.bbi.2006.05.002\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Aggression, TNF-α, IDO1, BCG, Etanercept, Minocycline","lastPublishedDoi":"10.21203/rs.3.rs-9174921/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9174921/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAggression is linked to systemic inflammation and serotonergic dysfunction. Tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine, disrupts serotonin synthesis by upregulating indoleamine 2,3-dioxygenase 1 (IDO1), which diverts tryptophan metabolism away from serotonin production. This study investigated whether inhibiting the TNF-α/IDO1 signaling pathway could reduce aggressive behavior. Aggression-like behaviors were induced in mice using Bacillus Calmette\u0026ndash;Gu\u0026eacute;rin (BCG), known to elevate systemic TNF-α and reduce brain serotonin. Behavioral assessments included the Social Aggression Test (SAT), Rod Biting Test (RBT), and locomotor activity. Biochemical analyses of TNF-α (plasma and amygdala) and serotonin (amygdala) were conducted using ELISA and HPLC. Treatment groups received either the TNF-α inhibitor etanercept, the IDO1 inhibitor minocycline, or both. BCG-inoculated mice exhibited increased aggression and reduced serotonin levels, alongside elevated TNF-α in the amygdala. Etanercept significantly reduced aggressive behavior and restored serotonin levels. Co-treatment with minocycline further enhanced these effects. Locomotor activity remained unchanged across all groups. TNF-α inhibition mitigates aggression by restoring serotonin levels, likely through suppression of IDO1 activity. Co-inhibition of IDO1 enhances this effect, highlighting the TNF-α/IDO1 pathway as a promising target for managing aggression.\u003c/p\u003e","manuscriptTitle":"Inhibition of the TNF-α/IDO1 Axis Restores Brain Serotonin and Mitigates Aggression-like Phenotypes in BCG-inoculated Mice","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-03-25 15:52:56","doi":"10.21203/rs.3.rs-9174921/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"fabf9e73-0c18-4332-a824-1334e7bc131f","owner":[],"postedDate":"March 25th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-03-25T15:52:56+00:00","versionOfRecord":[],"versionCreatedAt":"2026-03-25 15:52:56","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9174921","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9174921","identity":"rs-9174921","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00